Hapvida Participacoes e Investimentos (HAPV3) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
3 Feb, 2026Executive summary
Successfully concluded a major integration cycle, unifying all acquired entities and systems by December 2024, positioning for a new growth phase in 2025 with a focus on digitalization and network expansion.
Maintained recovery trajectory with strong cash generation, reduced leverage, margin improvement, and increased investments in network expansion and systems integration.
Overcame significant operational challenges in 2024, including major floods and a dengue epidemic, while maintaining service quality and controlling claims.
Achieved historic improvements in customer satisfaction and operational efficiency, with a strong emphasis on technology and AI-driven initiatives for 2025.
Integration of Hapvida and Notre Dame Intermédica operations, especially in São Paulo, improved care quality and beneficiary satisfaction.
Financial highlights
Net revenue reached R$7,472.4 million in 4Q24 (+7.8% vs. 4Q23) and R$28,952.1 million in 2024 (+5.8% vs. 2023), driven by health and dental plan growth and price adjustments.
Adjusted EBITDA was R$1,063 million in 4Q24 (+19.4% vs. 4Q23) and R$3,795 million in 2024 (+34.9% vs. 2023), with margin expansion.
Adjusted net income totaled R$514.7 million in 4Q24 (+98.8% vs. 4Q23) and R$1,836.3 million in 2024 (+170% vs. 2023).
Cash MLR improved to 67.9% in 4Q24 (down 1.4 p.p. vs. 4Q23) and 69.2% in 2024 (down 2.7 p.p. vs. 2023).
Free cash flow was R$1,517.6 million in 2024, with net cash increasing by R$1,365.1 million to R$9,225.0 million at year-end.
Outlook and guidance
Positive outlook for 2025, expecting average contract readjustments to normalize to pre-pandemic levels and continued organic growth in beneficiaries.
Started 2025 with the inauguration of three new hospitals in strategic regions, aiming to further expand and improve care quality.
Focus on capturing synergies, digital transformation, and further expansion and upgrading of the healthcare network.
Anticipates further cost efficiencies and margin improvements as integration and digitalization efforts mature.
Management highlights strong free cash flow conversion and balanced leverage, with net debt/EBITDA at 1.06x.
Latest events from Hapvida Participacoes e Investimentos
- Net revenue rose 5.9% YoY, but margin and beneficiary declines drive transformation focus.HAPV3
Q4 202519 Mar 2026 - Adjusted EBITDA rose 58% year-over-year, with strong margin recovery and cash flow.HAPV3
Q2 20242 Feb 2026 - Revenue and margins improved, with net debt at 0.97x EBITDA and strong cash flow.HAPV3
Q3 202414 Jan 2026 - Revenue up 7.3% YoY, strong beneficiary growth, but SUS provision hit earnings.HAPV3
Q2 202523 Nov 2025 - Revenue up 7.3% YoY, EBITDA stable, leverage down, but net income fell on legal costs.HAPV3
Q1 202518 Nov 2025 - Net revenue up 6.0% YoY, adjusted EBITDA at R$746.4M, and cash MLR at 75.2%.HAPV3
Q3 202513 Nov 2025